Download PDF
Semin Thromb Hemost 2003; 29(6): 645-652
DOI: 10.1055/s-2004-815632
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Treatment of Severe Preeclampsia with Antithrombin Concentrate: Results of a Prospective Feasibility Study

Takao Kobayashi1,2 , Toshihiko Terao3 , Tsuyomu Ikenoue4 , Hiroshi Sameshima4 , Masao Nakabayashi5 , Yayoi Kajiwara6 , Masahiro Maki7 ,  BI 51.017 Study Group8
  • 1Professor, Shinshu University of Health Sciences, Matsumoto City, Nagano Prefecture, Japan
  • 2Shinshu University of Health Sciences, Matsumoto City, Nagano Prefecture, Japan
  • 3Department of Obstetrics & Gynecology, Hamamatsu University School of Medicine, Hamamatsu City, Shizuoka
  • 4Department of Obstetrics & Gynecology, Miyazaki Medical College, Kiyotake Town, Miyazaki
  • 5Department of Obstetrics & Gynecology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo
  • 6Department of Productivity, Portfolio & Project Management, Aventis Pharma Ltd., Minato-ku, Tokyo
  • 7Department of Obstetrics & Gynecology, Akita University School of Medicine, Akita City, Akita, Japan
  • 8the members of BI51.017 Study Group are listed in the Acknowledgments
Further Information

Publication History

Publication Date:
13 January 2004 (online)

    Permissions and Reprints

ABSTRACT

The prospective feasibility study was designed to determine whether treatment with antithrombin (AT) concentrates could be used for patients with severe preeclampsia to provide clinical efficacy without the full systemic antihypertensive drug. Twenty-nine severe preeclamptic patients (24 to 36 weeks of gestation, gestosis index [GI] ≥ 6 points) were randomized to receive AT (1500 U/day) or not. AT was given intravenously once daily for 7 consecutive days. Twenty-four hours of continuous infusion of 5000 U/day of unfractionated heparin was given simultaneously in both groups. There were no statistical differences in the clinical profiles of the two groups. Maternal symptoms were evaluated from the difference of GI before and after treatment, and fetal findings were evaluated from the changes of the biophysical profile score. Improvement was significantly greater in the AT group for both the GI (P = 0.046) and the biophysical profile score (P = 0.022). The improvement of coagulation parameters was also evaluated. The improvement of plasmin-plasmin inhibitor complex (PPIC), D-dimer levels, and platelet counts was observed in the AT group compared with the non-AT group. The coagulation index as a composite coagulation test parameter showed a significantly improvement in the AT group. No adverse events related to AT were observed. Given that AT plus heparin was significantly better than treatment with heparin alone for improvement of both GI and biophysical profile of infant, it is suggested that therapy with AT alone might be effective enough for severe preeclampsia.

KEYWORDS

Preeclampsia - hypercoagulable state - vasoconstriction - antithrombin (AT) concentrate - biophysical profile

REFERENCES

  • 1 Mushambi M C, Halligan A W, Williamson K. Recent developments in the pathophysiology and management of pre-eclampsia.  Br J Anaesth . 1996;  76 133-148
    PubMedGoogle Scholar
  • 2 Rabiet M J, Plantier J L, Dejana E. Thrombin-induced endothelial cell dysfunction.  Br Med Bull . 1992;  50 936-965
    PubMedGoogle Scholar
  • 3 Kobayashi T, Tokunaga N, Sugimura M, Kanayama N, Terao T. Vasospasms are characteristic in cases with eclampsia/preeclampsia and HELLP syndrome:proposal of angiospastic syndrome of pregnancy.  Semin Thromb Hemost . 2001;  27 131-135
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Kobayashi T, Sugimura M, Naruse H. et al . Anticholinergics induce eclamptic seizures.  Semin Thromb Hemost . 2002;  28 511-514
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Terao T, Maki M, Ikenoue T. et al . The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy.  Gynecol Obstet Invest . 1991;  31 74-85
    PubMedGoogle Scholar
  • 6 Perry K G, Martin J N. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia.  Clin Obstet Gynecol . 1992;  35 338-350
    PubMedGoogle Scholar
  • 7 Weiner C P, Brandt J. Plasma antithrombin III activity: an aid in the diagnosis of preeclampsia-eclampsia.  Am J Obstet Gynecol . 1982;  142 275-281
    PubMedGoogle Scholar
  • 8 Kobayashi T, Sugimura M, Kanayama N. et al . Coagulation/ fibrinolysis disorders in patients with severe preeclampsia.  Semin Thromb Hemost . 1999;  25 451-454
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Kobayashi T, Tokunaga N, Sugimura M, Kanayama N, Terao T. Predictive values of coagulation/fibrinolysis parameters for the termination of pregnancy complicated by severe preeclampsia.  Semin Thromb Hemost . 2001;  27 137-141
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Kobayashi T, Sumimoto K, Tokunaga N. et al . Coagulation index to distinguish severe preeclampsia from normal pregnancy.  Semin Thromb Hemost . 2002;  28 495-499
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Weenink G H, Treffers P E, Vijin P, Smorenberg-Schoorl M E, ten Cate W J. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity.  Am J Obstet Gynecol . 1984;  148 1092-1097
    PubMedGoogle Scholar
  • 12 He S, Bremme K, Blombäck M. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia.  Blood Coagul Fibrinolysis . 1997;  8 232-238
    CrossrefPubMedGoogle Scholar
  • 13 The Japan Society of Obstetrics and Gynecology. The definition of pre-eclampsia in Japan.  Acta Obstet Gynaecol Jpn . 1992;  44 5-6
    PubMedGoogle Scholar
  • 14 Von Goecke C, Schwabe G. Vorschlag einer Stadien-Einteilung der Gestose.  Zbl Gynäk . 1965;  87 1439-1443
    PubMedGoogle Scholar
  • 15 Jürgens H, Dichmann R. Gestosis index and perinatal mortality.  Zbl Gynäk . 1975;  97 1201-1211
    PubMedGoogle Scholar
  • 16 Kaminski K, Rechberger T. Concentration of digoxin-like immunoreactive substance in patients with preeclampsia and its relation to severity of pregnancy-induced hypertension.  Am J Obstet Gynecol . 1991;  165 733-736
    PubMedGoogle Scholar
  • 17 Manning F A, Lange I R, Morrison I, Harman C R. Fetal biophysical profile score and the nonstress test: a comparative trial.  Obstet Gynecol . 1984;  64 326-331
    PubMedGoogle Scholar
  • 18 Harpel P C. Blood proteolytic enzyme inhibitors: their role in modulating blood coagulation and fibrinolytic enzyme pathways. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis Philadelphia: J.B. Lippincott 1982: 738-741
    Google Scholar
  • 19 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor.  J Biol Chem . 1973;  248 6490-6405
    PubMedGoogle Scholar
  • 20 Shinyama H, Akira T, Uchida T, Hirahara K, Watanabe M, Kagitani Y. Antithrombin III prevents renal dysfunction and hypertension induced by enhanced intravascular coagulation in pregnant rats: pharmacological confirmation of the benefits of treatment with antithrombin III in preeclampsia.  J Cardiovasc Pharmacol . 1996;  27 702-711
    CrossrefPubMedGoogle Scholar
  • 21 Maki M, Terao T, Ikenoue T. et al . Clinical evaluation of antithrombin III concentrate (BI6.013) for disseminated intravascular coagulation in obstetrics.  Gynecol Obstet Invest . 1987;  23 230-240
    PubMedGoogle Scholar
  • 22 Fujiwara K, Okita K, Akamatsu K. et al . Antithrombin III concentrate in the treatment of fulminant hepatic failure.  Gastroenterol Jpn . 1988;  23 423-427
    PubMedGoogle Scholar
  • 23 Weenink G H, ten Cate W J, Treffers P E. Hypertensive disorders.  Clin Obstet Gynecol . 1985;  28 37-45
    PubMedGoogle Scholar
  • 24 Terao T, Kobayashi T, Imai N, Oda H, Karasawa T. Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment with AT-III concentrate.  Asia-Oceania J Obstet Gynecol . 1989;  15 25-32
    PubMedGoogle Scholar
  • 25 Kwawukume E Y, Ghosh T S. Oral nifedipine therapy in the management of severe preeclampsia.  Int J Gynecol Obstet . 1995;  49 265-269
    CrossrefPubMedGoogle Scholar
  • 26 Sibai B M. Treatment of hypertension in pregnant women.  N Engl J Med . 1996;  335 257-265
    CrossrefPubMedGoogle Scholar
  • 27 Montan S. Medical prevention of pre-eclampsia.  Acta Obstet Gynecol Scand Suppl . 1997;  164 111-115
    PubMedGoogle Scholar
  • 28 Wacker J, Werner P, Walter-Sank I, Bastert G. Treatment of hypertension in patients with preeclampsia: a prospective parallel-group study comparing dihydralazine with urapidil.  Nephrol Dial Transplant . 1998;  13 318-325
    PubMedGoogle Scholar
  • 29 Sibai B M. Prevention of preeclampsia: a big disappointment.  Am J Obstet Gynecol . 1998;  179 1275-1278
    PubMedGoogle Scholar
  • 30 Marcus A J. Platelet aggregation. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis Philadelphia: J.B. Lippincott 1982: 380-389.
    Google Scholar
  • 31 White R P, Chapleau C E, Dngdale M, Robertson J T. Cerebral arterial contractions induced by human and bovine thrombin.  Stroke . 1980;  11 363-368.
    PubMedGoogle Scholar
  • 32 Fenton J W. Thrombin specificity.  Ann N Y Acad Sci . 1981;  370 468-495
    PubMedGoogle Scholar
  • 33 Minnear F L, Martin D, Hill L, Taylor A E, Malik A B. Lung morphological and permeability changes induced by intravascular coagulation dogs.  Am J Physiol . 1987;  253 H634-H644
    PubMedGoogle Scholar
  • 34 Zimmerman G A, Mclntyre T M, Prescott S M. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro.  J Clin Invest . 1985;  76 2235-2246
    PubMedGoogle Scholar
  • 35 Mutoh S, Komatsu Y, Kobayashi M. et al . Plasma coagulation-fibrinolysis system in the utero-placental circulation in severe preeclampsia: especially on tPA/PAI-1/C and active PAI-1.  Jpn J Thromb Hemost . 1994;  5 54-65
    PubMedGoogle Scholar